← Back to Analyst Consensus 
BBNX Buy
Beta Bionics, Inc.
Current Price —
Implied Upside —
Analysts 19
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 12, 2026 | Jefferies | initiate | — → Buy | — | 52% |
| Sep 24, 2026 | Truist Securities | maintain | Buy → Buy | — | 55% |
| Sep 23, 2026 | Wells Fargo | initiate | — → Overweight | — | 54% |
| Sep 15, 2026 | B of A Securities | maintain | Neutral → Neutral | — | 53% |
| Sep 15, 2026 | Truist Securities | reiterate | Buy → Buy | — | 55% |
| Sep 15, 2026 | Baird | maintain | Neutral → Neutral | — | 55% |
| Sep 14, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Aug 21, 2026 | William Blair | initiate | — → Market Perform | — | 48% |
| Jul 15, 2026 | Goldman Sachs | maintain | Buy → Buy | — | 54% |
| Jul 13, 2026 | Truist Securities | maintain | Buy → Buy | — | 55% |
| May 27, 2026 | Goldman Sachs | maintain | Buy → Buy | — | 54% |
| May 18, 2026 | B of A Securities | maintain | Neutral → Neutral | — | 53% |
| Apr 22, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Apr 22, 2026 | Stifel | maintain | Buy → Buy | — | 54% |
| Apr 15, 2026 | Truist Securities | maintain | Buy → Buy | — | 55% |
| Apr 9, 2026 | Goldman Sachs | maintain | Buy → Buy | — | 54% |
| Feb 18, 2026 | Stifel | maintain | Buy → Buy | $22 | 54% |
| Feb 18, 2026 | Baird | maintain | Neutral → Neutral | $14 | 55% |
| Feb 4, 2026 | Stifel | maintain | Buy → Buy | $25 | 54% |
| Feb 2, 2026 | Truist Securities | maintain | Buy → Buy | $25 | 55% |
| Jan 27, 2026 | TD Cowen | initiate | — → Hold | $17 | 54% |
| Jan 9, 2026 | Lake Street | maintain | Buy → Buy | $40 | 47% |
| Jan 5, 2026 | B of A Securities | maintain | Buy → Buy | $33 | 53% |
| Dec 18, 2025 | Truist Securities | maintain | Buy → Buy | $37 | 55% |
| Oct 29, 2025 | Goldman Sachs | maintain | Buy → Buy | $33 | 54% |
| Oct 29, 2025 | Stifel | reiterate | Buy → Buy | $31 | 54% |
| Oct 29, 2025 | Truist Securities | reiterate | Buy → Buy | $32 | 55% |
| Oct 29, 2025 | Piper Sandler | reiterate | Overweight → Overweight | $32 | 54% |
| Oct 1, 2025 | Goldman Sachs | upgrade | Neutral → Buy | $26 | 54% |
| Sep 22, 2025 | Truist Securities | maintain | Buy → Buy | $28 | 55% |
| Jul 30, 2025 | Truist Securities | maintain | Buy → Buy | $21 | 55% |
| Jul 30, 2025 | Baird | maintain | Neutral → Neutral | $17 | 55% |
| Jun 16, 2025 | Truist Securities | initiate | — → Buy | $26 | 55% |
| May 30, 2025 | Goldman Sachs | initiate | — → Neutral | $16 | 54% |
| May 30, 2025 | Wolfe Research | initiate | — → Outperform | $20 | 54% |
| Feb 24, 2025 | Stifel | initiate | — → Buy | $25 | 54% |
| Feb 24, 2025 | Lake Street | initiate | — → Buy | $30 | 47% |
| Feb 24, 2025 | Piper Sandler | initiate | — → Overweight | $26 | 54% |
| Feb 24, 2025 | Leerink Partners | initiate | — → Outperform | $28 | 51% |
| Feb 20, 2025 | Ladenburg Thalmann | initiate | — → Buy | $31 | 45% |
| Feb 20, 2025 | Baird | initiate | — → Neutral | $20 | 55% |
Price Target Trend
Apr 10, 2026 Oct 27, 2026
EPS Estimates
+1q —
0q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days